Please enable JavaScript to continue using this application.

Compare $COAG vs $INBX | Chartloom

Compare

$COAG vs $INBX

Hemab Therapeutics Holdings Inc · Inhibrx Biosciences Inc

COAG

Hemab Therapeutics Holdings Inc

INBX

Inhibrx Biosciences Inc

Compare $COAG vs $INBX

Comparing Hemab Therapeutics Holdings Inc and Inhibrx Biosciences Inc

COAGHemab Therapeutics Holdings Inc

INBXInhibrx Biosciences Inc

COAGHemab Therapeutics Holdings Inc

Market cap

$1.48B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-7.0%

52W performance

-7.0%

FCF yield

0.0%

INBXInhibrx Biosciences Inc

Market cap

$1.39B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

26.6%

52W performance

182.7%

FCF yield

-9.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

COAG

INBX

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

INBX

Inhibrx Biosciences Inc

Market Cap

COAG$1.48B

INBX$1.39B

Enterprise Value

COAG$1.24B

INBX$1.44B

Price

COAG$31.62

INBX$95.01

P/E Ratio

COAGN/A

INBXN/A

P/S Ratio

COAG0.00x

INBX1,019.62x

EV/Sales

COAG0.00x

INBX1,050.29x

EV/EBITDA

COAG0.00x

INBX0.85x

P/B Ratio

COAG3.20x

INBX178.59x

P/FCF Ratio

COAGN/A

INBXN/A

EV/FCF

COAG0.00x

INBX-10.89x

PEG Ratio

COAGN/A

INBXN/A

Forward P/E (NTM)

COAGN/A

INBXN/A

Forward P/S (NTM)

COAGN/A

INBXN/A

Revenue (TTM)

COAG$0

INBX$0

Revenue Growth (YoY)

COAGN/A

INBX-100.0%

Forward Rev Growth

COAG1014.0%

INBX282.8%

Gross Margin (TTM)

COAG0.0%

INBX0.0%

Operating Margin (TTM)

COAG0.0%

INBX0.0%

EBITDA Margin (TTM)

COAG0.0%

INBX0.0%

Net Margin (TTM)

COAG0.0%

INBX0.0%

FCF Margin (TTM)

COAGN/A

INBXN/A

Net Income (TTM)

COAG$-47M

INBX$-138M

FCF (TTM)

COAG$0

INBX$-132M

EPS (TTM)

COAG-$1.00

INBX-$8.82

ROE (TTM)

COAG0.0%

INBX-26956.0%

ROA (TTM)

COAG0.0%

INBX-8348.0%

ROIC (TTM)

COAG0.0%

INBX-9241.0%

Cash

COAG$237M

INBX$133M

Debt

COAG$0

INBX$176M

Net Cash/Debt

COAG$237M

INBX$-43M

Current Ratio (TTM)

COAG35.85x

INBX5.07x

Quick Ratio (TTM)

COAG35.48x

INBX4.76x

Debt/Equity (TTM)

COAG0.00x

INBX12.58x

Debt/Assets (TTM)

COAG0.0%

INBX0.0%

Interest Coverage (TTM)

COAGN/A

INBXN/A

Net Debt/EBITDA (TTM)

COAG0.00x

INBX0.00x

Beta

COAG-0.87

INBX3.17

52W Performance

COAG-7.0%

INBX182.7%

YTD Performance

COAG-7.0%

INBX26.6%

% from 52W High

COAG-42.9%

INBX-38.8%

% from 52W Low

COAG37.5%

INBX237.4%

Asset Turnover (TTM)

COAG0.00x

INBX0.01x

FCF Yield (TTM)

COAG0.0%

INBX-9.5%

Earnings Yield (TTM)

COAG-3.2%

INBX-9.9%

Dividend Yield (TTM)

COAGN/A

INBXN/A

Rule of 40

COAG0.0

INBX-100.0

EV/GP/RG

COAGN/A

INBXN/A

Ticker research

View COAG research View INBX research

Metric	COAG Hemab Therapeutics Holdings Inc	INBX Inhibrx Biosciences Inc
Market & Valuation
Market Cap	$1.48B	$1.39B
Enterprise Value	$1.24B	$1.44B
Price	$31.62	$95.01
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1,019.62x
EV/Sales	0.00x	1,050.29x
EV/EBITDA	0.00x	0.85x
P/B Ratio	3.20x	178.59x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-10.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	-100.0%
Forward Rev Growth	1014.0%	282.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-47M	$-138M
FCF (TTM)	$0	$-132M
EPS (TTM)	-$1.00	-$8.82
ROE (TTM)	0.0%	-26956.0%
ROA (TTM)	0.0%	-8348.0%
ROIC (TTM)	0.0%	-9241.0%
Financial Health
Cash	$237M	$133M
Debt	$0	$176M
Net Cash/Debt	$237M	$-43M
Current Ratio (TTM)	35.85x	5.07x
Quick Ratio (TTM)	35.48x	4.76x
Debt/Equity (TTM)	0.00x	12.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	3.17
52W Performance	-7.0%	182.7%
YTD Performance	-7.0%	26.6%
% from 52W High	-42.9%	-38.8%
% from 52W Low	37.5%	237.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	0.0%	-9.5%
Earnings Yield (TTM)	-3.2%	-9.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View COAG research	View INBX research

Valuation

P/S Ratio

COAG

0.00x

INBX

1,019.62x

EV/FCF

INBX

-10.89x

COAG

0.00x

Growth & revenue

Revenue Growth TTM

INBX

-100.0%

Forward Revenue Growth

COAG

1014.0%

INBX

282.8%

Profitability & performance

Gross Margin

COAG

0.0%

INBX

0.0%

ROE

COAG

0.0%

INBX

-26956.0%

FCF Yield %

COAG

0.0%

INBX

-9.5%

52-Week Performance

INBX

182.7%

COAG

-7.0%

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

INBX

Inhibrx Biosciences Inc

Market Cap

COAG$1.48B

INBX$1.39B

Enterprise Value

COAG$1.24B

INBX$1.44B

Price

COAG$31.62

INBX$95.01

P/E Ratio

COAGN/A

INBXN/A

P/S Ratio

COAG0.00x

INBX1,019.62x

EV/Sales

COAG0.00x

INBX1,050.29x

EV/EBITDA

COAG0.00x

INBX0.85x

P/B Ratio

COAG3.20x

INBX178.59x

P/FCF Ratio

COAGN/A

INBXN/A

EV/FCF

COAG0.00x

INBX-10.89x

PEG Ratio

COAGN/A

INBXN/A

Forward P/E (NTM)

COAGN/A

INBXN/A

Forward P/S (NTM)

COAGN/A

INBXN/A

Revenue (TTM)

COAG$0

INBX$0

Revenue Growth (YoY)

COAGN/A

INBX-100.0%

Forward Rev Growth

COAG1014.0%

INBX282.8%

Gross Margin (TTM)

COAG0.0%

INBX0.0%

Operating Margin (TTM)

COAG0.0%

INBX0.0%

EBITDA Margin (TTM)

COAG0.0%

INBX0.0%

Net Margin (TTM)

COAG0.0%

INBX0.0%

FCF Margin (TTM)

COAGN/A

INBXN/A

Net Income (TTM)

COAG$-47M

INBX$-138M

FCF (TTM)

COAG$0

INBX$-132M

EPS (TTM)

COAG-$1.00

INBX-$8.82

ROE (TTM)

COAG0.0%

INBX-26956.0%

ROA (TTM)

COAG0.0%

INBX-8348.0%

ROIC (TTM)

COAG0.0%

INBX-9241.0%

Cash

COAG$237M

INBX$133M

Debt

COAG$0

INBX$176M

Net Cash/Debt

COAG$237M

INBX$-43M

Current Ratio (TTM)

COAG35.85x

INBX5.07x

Quick Ratio (TTM)

COAG35.48x

INBX4.76x

Debt/Equity (TTM)

COAG0.00x

INBX12.58x

Debt/Assets (TTM)

COAG0.0%

INBX0.0%

Interest Coverage (TTM)

COAGN/A

INBXN/A

Net Debt/EBITDA (TTM)

COAG0.00x

INBX0.00x

Beta

COAG-0.87

INBX3.17

52W Performance

COAG-7.0%

INBX182.7%

YTD Performance

COAG-7.0%

INBX26.6%

% from 52W High

COAG-42.9%

INBX-38.8%

% from 52W Low

COAG37.5%

INBX237.4%

Asset Turnover (TTM)

COAG0.00x

INBX0.01x

FCF Yield (TTM)

COAG0.0%

INBX-9.5%

Earnings Yield (TTM)

COAG-3.2%

INBX-9.9%

Dividend Yield (TTM)

COAGN/A

INBXN/A

Rule of 40

COAG0.0

INBX-100.0

EV/GP/RG

COAGN/A

INBXN/A

Ticker research

View COAG research View INBX research

Metric	COAG Hemab Therapeutics Holdings Inc	INBX Inhibrx Biosciences Inc
Market & Valuation
Market Cap	$1.48B	$1.39B
Enterprise Value	$1.24B	$1.44B
Price	$31.62	$95.01
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	1,019.62x
EV/Sales	0.00x	1,050.29x
EV/EBITDA	0.00x	0.85x
P/B Ratio	3.20x	178.59x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-10.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	-100.0%
Forward Rev Growth	1014.0%	282.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-47M	$-138M
FCF (TTM)	$0	$-132M
EPS (TTM)	-$1.00	-$8.82
ROE (TTM)	0.0%	-26956.0%
ROA (TTM)	0.0%	-8348.0%
ROIC (TTM)	0.0%	-9241.0%
Financial Health
Cash	$237M	$133M
Debt	$0	$176M
Net Cash/Debt	$237M	$-43M
Current Ratio (TTM)	35.85x	5.07x
Quick Ratio (TTM)	35.48x	4.76x
Debt/Equity (TTM)	0.00x	12.58x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	3.17
52W Performance	-7.0%	182.7%
YTD Performance	-7.0%	26.6%
% from 52W High	-42.9%	-38.8%
% from 52W Low	37.5%	237.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	0.0%	-9.5%
Earnings Yield (TTM)	-3.2%	-9.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-100.0
EV/GP/RG	N/A	N/A
Ticker research	View COAG research	View INBX research